- Conditions
- Gout, Hyperuricemia, Arthritis, Joint Disease, Renal Insufficiency
- Interventions
- Placebo, Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Peoria, Arizona • Irvine, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 856
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Skin Laxity
- Interventions
- Ulthera® System Treatment, Heavy Water
- Device · Other
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Congenital Heart Disease
- Interventions
- Treprostinil, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Smith-Lemli-Opitz Syndrome
- Interventions
- diet
- Behavioral
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Anesthesia; Adverse Effect, Congenital Heart Disease, Neurodevelopmental Disorders
- Interventions
- Isoflurane, Fentanyl (high dose), Fentanyl (low dose)
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 1 Day to 36 Months
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Hemophilia A, Prophylaxis of Bleeding
- Interventions
- Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Sodium Nitrate, Sodium Nitrate - double dose, Placebo, Increased exercise intensity
- Dietary Supplement · Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 15 Years to 45 Years · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections, Hemophilia A
- Interventions
- Ibuprofen, Zidovudine
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Gaucher Disease Type 1, Gaucher Disease Type 3
- Interventions
- Velaglucerase alfa
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 4 Years to 14 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
- Interventions
- telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
- Behavioral · Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Atopic Dermatitis
- Interventions
- Skin Cleanser Combination No.1
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2031 – 2039
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cystic Fibrosis
- Interventions
- ivacaftor, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hypercholesterolemia, Familial, Hyperlipidemia
- Interventions
- torcetrapib/atorvastatin, atorvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 7
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Wilson Disease
- Interventions
- ALXN1840, Bupropion Hydrochloride
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
- Interventions
- dabrafenib, trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 99 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more
- Conditions
- Intellectual Disability, Down Syndrome
- Interventions
- Self-monitoring shopping intervention
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Hillsborough, New Jersey
- Conditions
- Atopic Dermatitis
- Interventions
- Isosorbide Diester Moisturizer, Control Moisturizer
- Other
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Preeclampsia
- Interventions
- Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 26 Weeks and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Marfan Syndrome
- Interventions
- Exercise Intervention Group
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
- Interventions
- Neurocognitive and psychosocial testing
- Behavioral
- Lead sponsor
- Connecticut Children's Medical Center
- Other
- Eligibility
- 2 Months to 89 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2030
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less)
- Interventions
- Financial Transfers
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Springfield, Massachusetts + 1 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more
- Conditions
- Gestational Diabetes Mellitus in Pregnancy, Pregestational Diabetes Mellitus, Neonatal Hypoglycemia
- Interventions
- Standard Intrapartum Glucose Target Range, Liberalized Intrapartum Glucose Target Range
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Female only
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Gut Health
- Interventions
- Butyrate Formulation, Butyrate + Polyphenol Formulation, Placebo
- Dietary Supplement
- Lead sponsor
- Supplement Formulators, Inc.
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida